Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026

Same author

Slow continuous ultrafiltration and prolonged intermittent renal replacement therapy: Tailoring renal replacement therapy in intensive care unit.

World journal of nephrology·2026

Same author

Glomerulonephritis through the lens of ultrasound and radiology.

World journal of nephrology·2026

Same author

PFA technology: Production, safety and wastewater deployment analysis.

Water research·2026

Same author

Artificial intelligence adoption in healthcare: a systematic review of implementation challenges and health services implications.

BMC health services research·2026

Same author

Decoupling Dissolution and Biological Kinetics in Polycaprolactone-Based Denitrification: Direct Determination of Yield and Maximum Specific Growth Rate.

Water environment research : a research publication of the Water Environment Federation·2026

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Emerging drugs for hyperphosphatemia.

Guido Bellinghieri¹, Domenico Santoro, Vincenzo Savica

¹University of Messina, Division of Nephrology and Dialysis, Policlinico Universitario, Viale Gazzi-98100, Messina, Italy.

Expert Opinion on Emerging Drugs

|September 19, 2007

Summary

This summary is machine-generated.

Hyperphosphatemia increases cardiovascular risk in dialysis patients. New salivary phosphate binders may offer a novel approach to reduce serum phosphate levels and improve patient outcomes.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Experiment Videos

Last Updated: Jul 11, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Area of Science:

Nephrology
Cardiovascular Medicine
Pharmacology

Background:

Cardiovascular mortality is the primary cause of death in uremic patients.
Hyperphosphatemia is an independent risk factor for cardiovascular morbidity and mortality in dialysis patients.
Dietary and dialysis methods often fail to achieve efficient phosphate control.

Purpose of the Study:

To review current phosphate binder therapies for chronic renal failure patients.
To discuss the limitations and side effects of traditional binders (aluminum and calcium-based).
To explore the potential of novel phosphate binders, including sevelamer hydrochloride and lanthanum carbonate, and investigate salivary phosphorus as a potential therapeutic target.

Main Methods:

Literature review of existing phosphate binders and their clinical effects.
Analysis of studies on sevelamer hydrochloride and lanthanum carbonate.
Examination of recent findings on the correlation between salivary and serum phosphorus in dialysis patients.

Main Results:

Aluminum salts have significant side effects due to systemic deposition.
Calcium-based binders increase calcium load and risk of metastatic calcification.
Sevelamer shows potential in reducing calcification and improving lipid metabolism; lanthanum carbonate offers similar phosphate control to calcium binders with less hypercalcemia, but requires long-term studies.

Conclusions:

Novel phosphate binders like sevelamer and lanthanum carbonate offer alternatives to traditional therapies.
The correlation between salivary and serum phosphorus suggests salivary phosphate binders could be a promising new strategy for managing hyperphosphatemia in uremic patients.